<\/p>\n
Erythego Gel<\/strong> is a topical gel containing brimonidine tartrate 0.33%<\/strong> from Ego Pharmaceuticals — the generic equivalent of Mirvaso. It is FDA-approved for the persistent facial erythema (background redness) of rosacea in adults<\/strong> and is the only topical specifically licensed to reduce the flushing and redness component, rather than the papules and pustules. Apply a pea-sized amount<\/strong> once daily in the morning to clean, dry skin. Onset: 30 minutes. Peak effect: 3–6 hours. Duration: approximately 12 hours.<\/strong> The effect wears off smoothly over the day. Brimonidine is an α2<\/sub>-adrenergic receptor agonist that causes local vasoconstriction of the superficial facial blood vessels — it does not treat the underlying inflammation of rosacea, so it is typically layered with azelaic acid 20%<\/a> \u03ae ivermectin 1%<\/a> (applied at night) for patients who have both erythema and inflammatory lesions. Rebound redness is the most talked-about side effect: about 10–20% of users experience it in the first weeks, and it almost always settles with continued daily use.<\/p>\n<\/div>\n \ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n \u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n Erythego Gel is a topical gel containing brimonidine tartrate 0.33%<\/strong>, manufactured by Ego Pharmaceuticals and supplied in a 30 g tube. It is the generic equivalent of Galderma’s Mirvaso<\/strong> (US) \/ Mirvaso (EU) — the first and still the only topical approved specifically to treat the persistent erythema (background redness)<\/strong> of rosacea in adults 18 and over.<\/p>\n Brimonidine is an α2<\/sub>-adrenergic receptor agonist. Applied to rosacea-affected facial skin, it binds receptors on the walls of superficial blood vessels and causes them to constrict, reducing the visible diameter and flow — giving a visibly less-red face within 30 minutes of application and holding that effect for most of the day.<\/p>\n The persistent redness of rosacea comes from two mechanisms: (1) permanent dilation (ectasia) of the superficial dermal blood vessels of the face, and (2) episodic vasodilator flushes triggered by heat, spicy food, alcohol, emotional stress, sun, and inflammatory mediators.<\/p>\n Brimonidine directly activates α2<\/sub> receptors on the smooth muscle lining these vessels, triggering physiological constriction. This reduces the amount of red-coloured blood visible through the skin, so the face visibly pales within 30 minutes of application. It is a cosmetic\/symptomatic<\/strong> effect — brimonidine does not treat the underlying rosacea inflammation or fibrovascular remodelling. Stopping the daily application returns the skin to its baseline redness.<\/p>\n Importantly, this means brimonidine is complementary to<\/strong> — not a replacement for — azelaic acid, topical ivermectin, or topical metronidazole, which address the inflammatory papule-and-pustule<\/em> component of rosacea. A large share of rosacea patients have both components and benefit from combined therapy.<\/p>\n Not approved for:<\/strong> papules, pustules, telangiectasia (visible broken capillaries do not constrict under brimonidine — they need laser or IPL), phymatous thickening, or ocular rosacea.<\/p>\n \u03a4\u03c5\u03c0\u03b9\u03ba\u03ae \u03b4\u03cc\u03c3\u03b7:<\/strong> a pea-sized amount once daily. Maximum 1 g (approximately five pea-sized amounts) across the whole face per 24 hours.<\/p>\n Expected effect curve (single application):<\/strong> visible redness reduction at 30 minutes; peak pallor at 3–6 hours; effect wears off smoothly over 10–12 hours.<\/p>\n Common (>3%):<\/strong><\/p>\n \u0391\u03c3\u03c5\u03bd\u03ae\u03b8\u03b9\u03c3\u03c4\u03b5\u03c2:<\/strong> worsening of rosacea symptoms, paraesthesia of the application area, dryness of the mouth, headache, dizziness, nasal congestion.<\/p>\n Rare but important:<\/strong> systemic α2<\/sub> effects — bradycardia, hypotension, drowsiness. Almost never seen with recommended once-daily facial dosing. Severe cases have been reported in children who accidentally ingested the gel.<\/p>\n Rebound redness is the main reason people discontinue brimonidine. The single best strategy is to start low<\/strong> — in the first week, use only a quarter of a pea-sized amount mixed into your morning moisturiser, then gradually build to a full pea over 2 weeks. This lets the vasculature adapt without triggering the steep constrict-then-rebound cycle.<\/p>\n If rebound does occur, do not re-apply brimonidine<\/strong> during the rebound — it escalates the cycle. Cold compresses, a break from spicy food\/alcohol\/heat for 48 hours, and maintenance azelaic acid or ivermectin will settle the flare. Restart brimonidine at a lower dose on your next scheduled morning.<\/p>\n \u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7 \u03ba\u03b1\u03b9 \u03b8\u03b7\u03bb\u03b1\u03c3\u03bc\u03cc\u03c2:<\/strong> brimonidine is FDA Pregnancy Category B. Systemic absorption from facial application is very low. Reasonable in pregnancy when the benefit exceeds the minimal risk; discuss with your obstetrician.<\/p>\n\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n
What Is Erythego Gel?<\/h2>\n
How Brimonidine Works on Rosacea Redness<\/h2>\n
Approved Use<\/h2>\n
\n
Erythego Gel Dosage and How to Apply<\/h2>\n
\n
\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n
\n
Managing Rebound Redness<\/h2>\n
Contraindications & Interactions<\/h2>\n
\n
Erythego Gel vs Other Rosacea Topicals<\/h2>\n